Target intelligence / Profile preview

Cytochrome b5 reductase 4 (CYB5R4)

Target
CYB5R4
Molecular classification
Enzyme, Oxidoreductase (flavohemoprotein family), NAD(P)H oxidase
01

Overview

Cytochrome b5 reductase 4 (CYB5R4) is a flavohemoprotein enzyme encoded by the CYB5R4 gene in humans. It contains functional domains found in both cytochrome b5 and cytochrome b5 reductase, and is involved primarily in electron transfer reactions, using NADH or NADPH to reduce membrane-bound electron acceptors. CYB5R4 is expressed in various subcellular membranes including the endoplasmic reticulum and mitochondria. In pancreatic beta-cells, CYB5R4 is critical for protecting cells against oxidative stress by preventing excessive buildup of reactive oxygen species. It also plays roles in lipid metabolism, xenobiotic detoxification, and glucose homeostasis. Mutations impacting the structural protein dynamics can lead to diseases such as methemoglobinemia. The enzyme is relevant to metabolic and oxidative stress-related disease mechanisms but is not currently targeted by approved drugs.

Other names
NCB5ORcb5/cb5RdJ676J13.1cytochrome b5 reductase 4CYB5R4
02

Mechanism of action

Drug mechanisms, if any, would involve modulation of redox activity or modulation of downstream oxidative stress pathways through enzyme inhibition or enhancement. However, no drugs are currently cited as acting directly on cytochrome b5 reductase 4 in the sources provided.

03

Biological functions

Redox regulation and electron transferProtection against oxidative stress (especially pancreatic beta-cells)Glucose homeostasisDetoxification pathways (via electron transfer)Endoplasmic reticulum stress responseParticipation in lipid metabolism and xenobiotic metabolism via interactions with cytochrome P450 monooxygenases
04

Disease associations

Diabetes (beta-cell stress and protection)Potential connection to metabolic and oxidative stress-related diseasesOther: Methemoglobinemia (when function is mutated/disrupted)
05

Safety considerations

No specific therapeutic safety concerns reported. General concerns relate to potential disruption of redox homeostasis, possible contribution to oxidative damage if enzyme activity is impaired, and implications in beta-cell viability.
06

Biomarkers

No specific biomarkers for patient selection or efficacy monitoring are reported. However, given the role in oxidative stress and beta-cell protection, dysfunction or expression changes of CYB5R4 could theoretically serve as a biomarker in diabetes research.

Beyond the preview

Go deeper on Cytochrome b5 reductase 4 (CYB5R4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome b5 reductase 4 (CYB5R4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call